logo
welcome
Benzinga

Benzinga

Analyst initiates coverage on ImmunityBio Inc. ( NASDAQ:IBRX) with a $30 price target

Benzinga
Summary
Nutrition label

64% Informative

EF Hutton has initiated coverage on ImmunityBio Inc. (NASDAQ:IBRX) The analyst initiates with a Buy rating and a price target of $ 30 .

The FDA approved ImmunityBio ’s Anktiva (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin ( BCG ) for BCG -unresponsive non-muscle invasive bladder cancer.

VR Score

54

Informative language

53

Neutral language

1

Article tone

formal

Language

English

Language complexity

68

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

detected

Known propaganda techniques

not detected

Time-value

medium-lived

Source diversity

1

Affiliate links

no affiliate links